Intellectual Property India Publishes Patent Application for 'Nucleocapsid Antigen Immunotherapy For Covid-19 Fusion Proteins And Methods Of Use' Filed by Vakston, Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517090834 A) filed by Vakston, Inc., Beverly, U.S.A., on Sept. 23, for 'nucleocapsid antigen immunotherapy for covid-19 fusion proteins and methods of use.'

Inventor(s) include Zion, Todd C.; and Lancaster, Thomas M.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation."

The patent application was internationally filed on Mar. 05, 2024, under International application No.PCT/US2024/018494.

Disclaimer: Curated by HT Syndication.